Trial Profile
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage III A-N2 Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 28 Nov 2018 New trial record